12 June 2025

Cancer risk in rheumatoid arthritis: anything new?

Is there a higher risk of cancer that comes with the disease? Or with the treatments? So many confounding parameters, such as disease duration, disease state, and disease activity come into play. A promising session explored comorbidities in Rheumatoid Arthritis, in particular cancer and cardiovascular events. Here are my takeaways.

12 June 2025

EULAR 2025 – Day 2 Report

Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few interesting presentations from today.

EULAR Daily Recap: Day 1 and 2

In axSpA patients with persistent pain, digital behavioral therapy (ACT-app) improved MPI pain-related life interference

Tweet Author

synovialjoints

Tweet Content

In axSpA patients with persistent pain, digital behavioral therapy (ACT-app) improved MPI pain-related life interference (β −0.36, 95% CI −0.73 to 0.01) and affective distress (β −0.40, 95% CI −0.84 to 0.003) vs standard of care (SOC). 43% completed full program. NPS 5.8. https://t.co/T6i9jkjcoU

Links

https://x.com/synovialjoints/status/1933212879395659819/photo/1

In AS (n=91,493), D2T defined as ≥2 b/tsDMARD classes plus elevated CRP. Risk factors: HLA-B27+ (OR 1.30), obesity (OR

Tweet Author

synovialjoints

Tweet Content

In AS (n=91,493), D2T defined as ≥2 b/tsDMARD classes plus elevated CRP. Risk factors: HLA-B27+ (OR 1.30), obesity (OR 1.20), depression (OR 1.22). D2T group had higher CRP (55.7 mg/L), BMI (31.1), and more EAMs (IBD, psoriasis, uveitis). Female predominance (56.9%)Abstract https://t.co/EHCt5wq4ot

Links

https://x.com/synovialjoints/status/1933214266368410018/photo/1

#EULAR2025 Abstr#OP0199 Validation of effective & safe HCQ blood levels monitoring (750-1150ng/mL) to guide optimal

Tweet Author

Yuz6Yusof

Tweet Content

#EULAR2025 Abstr#OP0199 Validation of effective & safe HCQ blood levels monitoring (750-1150ng/mL) to guide optimal dose. Particulary important in those with CKD Stage =>3 as considered high risk of toxicity. Next steps: wider availability & cost-effectiveness analysis @RheumNow https://t.co/WoVFolrmPA

Links

https://x.com/Yuz6Yusof/status/1933219999218384962/photo/1

#EULAR2025 Abstr#OP0200 Which social determinant of health in Europe affect #SLE outcomes so that these can be improved?

Tweet Author

Yuz6Yusof

Tweet Content

#EULAR2025 Abstr#OP0200 Which social determinant of health in Europe affect #SLE outcomes so that these can be improved? Registry in Sweden showed factors associated with damage/mortality: - Lower income & education, - No partner - On sick leave/disability benefits @RheumNow https://t.co/hgEfJzoqNg

Links

https://x.com/Yuz6Yusof/status/1933224308349768136/photo/1

#EULAR2025 Abstr#OP0201 Achieving treatment targets (LLDAS and/or DORIS) is more prognostically important. In Phase 3 RC

Tweet Author

Yuz6Yusof

Tweet Content

#EULAR2025 Abstr#OP0201 Achieving treatment targets (LLDAS and/or DORIS) is more prognostically important. In Phase 3 RCT, compared with PBO+SOC, Dapirolizumab+SOC resulted in higher rates of achievement and time in LLDAS and DORIS. LLDAS plateud after WK28 in PBO+SOC @RheumNow https://t.co/3Zd3jjx984

Links

https://x.com/Yuz6Yusof/status/1933229242558386493/photo/1

Using Combination csDMARDs in PsA

#EULAR2025 Abstr#OP0198 Long-term extension study of Phase 2 #SLE showed efficacy of Upadacitinib and UPA + Elsubrutinib

Tweet Author

Yuz6Yusof

Tweet Content

#EULAR2025 Abstr#OP0198 Long-term extension study of Phase 2 #SLE showed efficacy of Upadacitinib and UPA + Elsubrutinib were maintained through to Week 104. Those who switched from PBO at WK48 to UPA + ELSU also improved. No VTE or MACE. Is add-on ELSU really needed? @RheumNow https://t.co/x8NbAtsHh0

Links

https://x.com/Yuz6Yusof/status/1933198167765586162/photo/1

Topics

Cancer risk in rheumatoid arthritis: anything new?

EULAR Daily Recap: Day 1 and 2

In axSpA patients with persistent pain, digital behavioral therapy (ACT-app) improved MPI pain-related life interference

In AS (n=91,493), D2T defined as ≥2 b/tsDMARD classes plus elevated CRP. Risk factors: HLA-B27+ (OR 1.30), obesity (OR

#EULAR2025 Abstr#OP0199 Validation of effective & safe HCQ blood levels monitoring (750-1150ng/mL) to guide optimal

#EULAR2025 Abstr#OP0200 Which social determinant of health in Europe affect #SLE outcomes so that these can be improved?

#EULAR2025 Abstr#OP0201 Achieving treatment targets (LLDAS and/or DORIS) is more prognostically important. In Phase 3 RC

Using Combination csDMARDs in PsA

#EULAR2025 Abstr#OP0198 Long-term extension study of Phase 2 #SLE showed efficacy of Upadacitinib and UPA + Elsubrutinib

Do you get our email newsletter?